| Alcohol Metabolism, Functional Consequences and Apoptosis Signaling Mechanism |
Research Initiative |
FDA |
NIAAA |
The overall goals of these lab projects are to perform basic research to investigate the molecular mechanisms of cell/organ damage and to conduct translational research to prevent tissue damage caused by ethanol (binge alcohol) in the absence or presence of other risk factors. Alcohol and many other potentially toxic compounds e.g., acetaminophen (APAP), carbon tetrachloride (CCl4), cisplatin, lipopolysaccharide (LPS), thioacetamide (TAA), Western-style high fat diet (HFD), fructose, nicotine, etc. are known to stimulate cell/organ injury through increased oxidative and nitrative (nitro-oxidative) stress. |
| Alzheimers.gov Collaborations with Federal Agencies |
Public Education Campaign |
ACL, CDC, FDA, HRSA, IHS |
NIA |
In the course of updating and maintaining the Alzheimers.gov website, NIA consults with the federal partners through the NAPA Federal Subgroup and direct outreach to federal partners, such as contacting them regarding resource updates and clearing content through them. |
| Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks |
Research Initiative |
FDA |
NCATS, NCI, NIAAA, NINDS |
The mission of the Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership funded by the US Food and Drug Administration (FDA) is to identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic treatments for the benefit of the public health. |
| Annexes to the Playbook on Biological Incident Preparedness and Response - Clinical Research Response and Response Research Agenda |
Committee, Work group, Advisory group, or Task Force |
CDC, FDA |
NIAID |
Will define the process by which the United States will implement clinical trials of vaccines, diagnostics, or medical countermeasures in affected foreign countries even when there is no pre-existing research platform. To rapidly assess what knowledge gaps exist around a particular pathogen, its transmission, ecology, or management, in order to create a prioritized research agenda to guide medium and long-term research activities |
| Antibody Interest Group (ABIG) |
Committee, Work group, Advisory group, or Task Force |
FDA |
NCI, NHLBI, NIAID, NIDDK |
The NIH ABIG promotes information exchange and interaction among NIH scientists who work on various aspects of antibody engineering and therapy. The success of antibody therapy requires a thorough understanding of biological systems in relation to molecular and cell biology, immunology, biochemistry, and microbiology, as well as diseases such as cancer, autoimmunity, and infectious diseases. Interest in antibody therapy crosses traditional biomedical disciplinary boundaries. ABIG provides an open forum for multidisciplinary discussion among colleagues who otherwise may have limited interaction. The principal ABIG activities are monthly meetings on current topics as well as an annual symposium on the NIH campus. The monthly ABIG meetings are open to everyone interested. These meetings are devoted to research seminars on numerous aspects of antibody engineering and therapy presented by both NIH scientists and outside speakers. |
| Antimicrobial Drugs Advisory Committee |
Committee, Work group, Advisory group, or Task Force |
FDA |
NIAID |
The Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of infectious diseases and disorders and makes appropriate recommendations to the Food and Drug Administration (FDA) Commissioner. |
| Antiretroviral Pregnancy Registry |
Resource Development |
CDC |
NICHD |
This is a registry of use of antiretroviral drugs in pregnancy that is sponsored by various pharmaceutical companies and has a committee of external experts and government staff from the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). The registry provides a resource for clinicians and researchers to improve the healthcare quality and patient safety for HIV infected mothers and their infants. http://www.apregistry.com/ |
| AoURP and Veterans Administration |
Other |
AoA |
OD/All of Us |
Enrollment award to support engagement, enrollment and retention across VA clinic locations to facilitate participation in AOURP among the veteran population. Collaboration Type: award to the VA for enrollment and retention of AOU participants |
| ARPA-H Biomedical Data Fabric Toolbox program partnership |
Resource Development |
ARPA-H |
NCATS, NCI, NHLBI, NIBIB, NIEHS, OD/DPCPSI |
To support both the mission of ARPA-H to “Accelerate better health outcomes for everyone by supporting the development of high-impact solutions to society's most challenging health problems,” and the NCI’s vision to “Maximize cancer data availability, usability, and utility through forward-thinking policies and processes”, NCI and ARPA-H are partnering to advance Biomedical Data Fabric research efforts for cancer and chronic conditions by integrating advanced capabilities from across DARPA and NIH Institutes and Centers. |
| ARPA-H Glide Program |
Research Initiative |
ARPA-H, CDC, FDA |
NIA, NIAMS |
Groundbreaking Lymphatic Interventions and Drug Exploration. https://arpa-h.gov/explore-funding/programs/glide |